Northern epilepsy carrier status, and why one national number is the wrong answer

Almost every case of Northern epilepsy ever recorded comes from one district of Finland. That makes the usual way of quoting a carrier frequency, one number for one country, quietly wrong in both directions at once.

Also known as: CLN8 carrier, CLN8 disease, EPMR, northern epilepsy variant of neuronal ceroid lipofuscinosis.

Gene

CLN8

Inheritance

Autosomal recessive

Carrier frequency

roughly 1 in 135 across Finland, rising to about 1 in 46 in the Kainuu region of north-eastern Finland where almost all cases occur; very rare elsewhere in the world

What it is

Northern epilepsy is a recessive neurological condition caused by changes in CLN8, and it belongs to the neuronal ceroid lipofuscinoses, a family of inherited disorders in which storage material accumulates in nerve cells. Among that family it is the mildest and the slowest. The Finnish Disease Database describes a course in which development is normal until somewhere between five and ten years of age, when generalised tonic-clonic seizures begin. Seizure frequency rises towards puberty and then gradually falls away again. Cognitive decline follows the onset of seizures, and adults are typically left with moderate intellectual disability.

That trajectory, seizures that peak and then recede while cognition does not recover, is unusual enough that the condition was described clinically long before anyone knew which gene was responsible. Older literature refers to it by an abbreviation, EPMR, standing for a phrase built around a term for intellectual disability that is no longer used. The abbreviation still appears in databases and papers, so it is worth recognising, but CLN8 disease and Northern epilepsy are the names now in normal use.

The geography is not incidental. The Finnish Disease Database states plainly that Northern epilepsy has so far been detected only in a restricted district of Finland, Kainuu, in the north-east of the country, and that affected people carry a Finnish founder change in CLN8 in both copies of the gene. The variant, p.Arg24Gly, substitutes a glycine for an arginine near the start of a protein that sits in the membranes of the endoplasmic reticulum.

How it is inherited

Northern epilepsy is autosomal recessive. A carrier has one changed copy of CLN8 and one working copy, is healthy, and stays healthy. What carrier status affects is the arithmetic of a pregnancy: if a reproductive partner also carries a CLN8 change, each pregnancy carries a one in four chance of an affected child.

The carrier frequency shown near the top of this page is where this condition parts company with most of the others in this family, because it cannot honestly be given as a single figure. For most recessive conditions, quoting one national rate is a reasonable simplification. Do that here and you mislead two different readers in two different ways at the same time. Told the national Finnish figure, someone whose family comes from Kainuu is given a number well below their own, and someone whose family comes from anywhere else in Finland is given one well above theirs. The average of a strongly clustered distribution describes almost nobody in it.

This is what a founder effect looks like when it has not had time or migration enough to spread. A variant that entered one small settled population is carried forward through its descendants, and if those descendants stay put, so does the variant. The practical version of that for a reader is simple and slightly unusual for genetics: where your grandparents were born is genuinely relevant information here, and it is not information that lives in a DNA file.

What your raw DNA file can and cannot tell you

No consumer chip product reports this condition. 23andMe publishes the list of conditions its carrier status reports cover, and re-checked in August 2026 it runs to 46 conditions. Two of them are neuronal ceroid lipofuscinoses, the CLN5-related and PPT1-related forms, both of which are also enriched in Finland. Northern epilepsy is not among them. That comparison is the useful one, because it shows the gap is not about the disease family being obscure or hard to test. Two of this condition's close relatives made the list. This one is confined to a single Finnish district, and a district is not a market.

Aimosti does not issue carrier status from a chip file, for CLN8 or for any other gene. What our carrier module reads is a whole-genome VCF or gVCF, which covers the gene rather than a handful of chosen positions, and the founder change here is an ordinary single-base substitution that short-read sequencing calls without difficulty. So on this gene the file type is what decides whether an answer is possible at all: a sequencing file can carry one, and a chip export cannot.

Two limits are worth stating rather than leaving implied. First, this is not clinical carrier screening and it is not a substitute for a validated, gene-targeted carrier test ordered through a clinic; our panel deliberately leaves out conditions that a short-variant file cannot call. Second, a carrier result here says nothing about your own neurological health, and it is not a seizure risk assessment. If seizures are the reason you came to this page, that is a neurology question today, and no re-analysis of a consumer DNA file should be standing between you and asking it.

A genotyping chip reads only a few hundred thousand pre-selected positions, about 0.02% of your genome, chosen for common variation. It does not sequence the rest, so it cannot find the rare or novel pathogenic variants the clinical and carrier modules look for: a “no finding” from chip data means “this chip never looked”, far more so than with whole-genome sequencing. Chip data suits common-variant traits, pharmacogenomic tag SNPs, and haplogroup ancestry, not clinical or carrier screening.

Check what your file covers

Common questions

Sources

• MedlinePlus Genetics: CLN8 disease
• Finnish Disease Database (findis.org)
• Finnish Disease Database: Ceroid lipofuscinosis, neuronal, 8, northern epilepsy variant (EPMR)
• ClinVar: CLN8 c.70C>G (p.Arg24Gly), northern epilepsy variant
• GeneReviews: Genetic Disorders Associated with Founder Variants Common in the Finnish Population